Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

Article  PubMed  Google Scholar 

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1–9.

Article  Google Scholar 

Vencken PMLH, Kriege M, Hoogwerf D, Beugelink S, van der Burg MEL, Hooning MJ, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22:1346–52.

Article  CAS  PubMed  Google Scholar 

Tan DSP, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. BRCAness syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530–6.

Article  PubMed  Google Scholar 

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381:2391–402.

Article  PubMed  Google Scholar 

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med. 2019;381:2416–28.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with First-Line Chemotherapy and as maintenance therapy in Ovarian Cancer. N Engl J Med. 2019;381:2403–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib Maintenance Therapy in patients with recurrent ovarian Cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019;37:2968–73.

Article  PubMed  PubMed Central  Google Scholar 

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636–48.

Article  CAS  PubMed  Google Scholar 

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.

Article  CAS  PubMed  Google Scholar 

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379:2495–505.

Article  CAS  PubMed  Google Scholar 

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.

Article  CAS  PubMed  Google Scholar 

Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA, Bidziński M, et al. Olaparib Versus Nonplatinum Chemotherapy in patients with platinum-sensitive relapsed ovarian Cancer and a germline BRCA1/2 mutation (SOLO3): a Randomized Phase III Trial. J Clin Oncol. 2020;38:1164–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, et al. Olaparib plus Bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34:681–92.

Article  CAS  PubMed  Google Scholar 

Li N, Zhu J, Yin R, Wang J, Pan L, Kong B et al. Treatment with Niraparib Maintenance Therapy in patients with newly diagnosed Advanced Ovarian Cancer: a phase 3 Randomized Clinical Trial. JAMA Oncol. 2023;e232283.

DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-Year Follow-Up in patients with newly diagnosed Advanced Ovarian Cancer and a BRCA mutation: the SOLO1/GOG 3004 Trial. J Clin Oncol. 2023;41:609–17.

Article  CAS  PubMed  Google Scholar 

Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim J-W, et al. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: a multicentre retrospective study. Gynecol Oncol. 2022;165:97–104.

Article  CAS  PubMed  Google Scholar 

Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022;S0923-7534(22)01740-9.

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013;19:5485–93.

Article  CAS  PubMed  Google Scholar 

Gadducci A, Cosio S, Landoni F, Lissoni AA, Zola P, Laudani ME, et al. Response to Chemotherapy and clinical outcome of patients with recurrent epithelial ovarian Cancer after PARP inhibitor maintenance treatment: a Multicenter Retrospective Italian Study. Anticancer Res. 2022;42:2017–22.

Article  CAS  PubMed  Google Scholar 

Woodford RG, Zhou DD-X, Kok P-S, Lord SJ, Friedlander M, Marschner IC, et al. The validity of progression-free survival 2 as a surrogate trial end point for overall survival. Cancer. 2022;128:1449–57.

Article  PubMed  Google Scholar 

Oaknin A, Moore K, Colombo N, Scambia G, Kim B-G, Friedlander M, et al. Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): phase III SOLO1 trial. Ann Oncol. 2019;30:v405.

Article  Google Scholar 

Han SN, Monk BJ, Gonzalez-Martin A. Time to first subsequent therapy (TFST) and progression-free survival 2 (PFS2) from the phase 3 randomized, double-blind PRIMA/ENGOT-OV26/GOG-3012 study in patients with newly diagnosed ovarian cancer. Gynecol Oncol. 2020;159:18–9.

Article  Google Scholar 

Pautier P, Harter P, Pisano C, Cropet C, Hernando Polo S, Berger R, et al. Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial. JCO. 2021;39:5514–5514.

Article  Google Scholar 

Richard T, Penson RV, Valencia N, Colombo CA, Leath III. Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer. SGO. 2022.

Nakazawa H, Nagao S, Narita M, Shibutani T, Jimi T, Yano H, et al. Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy. J Obstet Gynaecol Res. 2022;48:1248–54.

Article  CAS  PubMed  Google Scholar 

Salarich AP, García IT, Burdalo BP, Gil-Martin M, Rodriguez JMP, Planas CF et al. Real-world-data on platinum outcomes after parp inhibitors progression in high grade serous ovarian cancer patients. International Journal of Gynecologic Cancer [Internet]. 2020 [cited 2022 Jun 19];30. Available from: https://ijgc.bmj.com/content/30/Suppl_4/A60.2.

Cerda VR, Lu D, Scott M, Kim KH, Rimel BJ, Kamrava M. Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study. Int J Gynecol Cancer. 2022;32:153–8.

Article  PubMed  Google Scholar 

Pujade-Lauraine E. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO/ENGOT Ov-38 trial. Ann Oncol. 2021;32:S1308–1309.

Article  Google Scholar 

Moubarak M, Harter P, Ataseven B, Traut A, Welz J, Baert T, et al. Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: a single institutional experience. Gynecol Oncol Rep. 2022;40:100939.

Article  PubMed  PubMed Central  Google Scholar 

McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. Int J Gynecol Cancer. 2020;30:1824–8.

Article  PubMed  PubMed Central  Google Scholar 

Park J, Lim MC, Lee J-K, Jeong DH, Kim SI, Choi MC, et al. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. J Gynecol Oncol. 2022;33:e12.

Article  CAS  PubMed  Google Scholar 

Essel KG, Behbakht K, Lai T, Hand L, Evans E, Dvorak J, et al. PARPi after PARPi in epithelial ovarian cancer. Gynecol Oncol Rep. 2021;35:100699.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18:773–91.

Article  PubMed  Google Scholar 

Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, et al. Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study. Gynecol Oncol. 2021;162:S3–4.

Article  Google Scholar 

Lee EK, Matulonis UA. PARP Inhibitor Resistance Mechanisms and implications for Post-progression Combination therapies. Cancers (Basel). 2020;12:E2054.

Article  Google Scholar 

Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, et al. EVOLVE: a Multicenter Open-label single-arm clinical and translational phase II trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clin Cancer Res. 2020;26:4206–15.

Article  CAS  PubMed